Over a thousand patients are still needed to participate in the McAllen area.
September 9, 2020 MCALLEN, TX – Enrollment for the Moderna COVID-19 vaccine clinical trial began at Centex Studies-McAllen in late-July. As of today, they have officially reached their first milestone and have enrolled over 400 patients. Over a thousand patients are still needed in the McAllen area and thousands more across the nation.
“The people of McAllen have gone above and beyond our expectations,” said Devora Torrence, President of Centex Studies. “They are so willing to play any part they can in beating this thing, and we couldn’t be more grateful for their contributions to research.”
The Moderna vaccine candidate is one of many projects backed by Operation Warp Speed with a goal to have an approved safe and effective vaccine by the end of 2020. This candidate is in phase 3 of the research process and needs a total of 30,000 patients nationwide. Centex-McAllen is responsible for enrolling about 1800 of those patients.
“We’ve always believed that we have some of the best people here in the Rio Grande Valley, but this global pandemic is really proving it,” said Dr. Joel Solis, Principle Investigator at Centex Studies-McAllen.
Those who qualify for and participate and participate in the study could receive access to the study vaccine and oversight from the Centex medical team at no cost, no insurance required. Compensation for study-related time and travel is also available. Centex Studies-McAllen is one of the top enrolling sites in the nation for the Latino population, but it’s not over yet! Those who wish to get involved in COVID-19 research studies can visit www.centexstudies.com or call 281-918-0048 for more information.
About Centex Studies
Centex Studies is a multi-specialty research organization with three locations across Texas and Louisiana. Research studies evaluating potential new options for several indications are enrolling now. There is no cost to participate, and compensation for study-related time and travel may be available.